Skip to main content
. 2021 Oct 18;125(12):1666–1676. doi: 10.1038/s41416-021-01560-1

Fig. 4. SLFN11 not significantly associated with sensitivity to the paclitaxel–carboplatin doublet in serous ovarian cancers.

Fig. 4

a Prevalence of SLFN11 by IHC H-score in serous ovarian cancer patient biopsies (n = 151), cut-off depicting the high and low SLFN11 subgroups shown, b representative images of high and low SLFN11 tumours. Black arrow indicates SLFN11-positive stromal cells used as an internal control. Scale bars at 100 µm. c SLFN11 H-score of patients divided by extreme good and poor clinical responders to carboplatin and paclitaxel doublet therapy. Median ± interquartile range shown. d SLFN11 IHC protein expression by H-score compared to NanoString quantified SLFN11 gene expression in the HGSOC patients. Dotted line indicates gene expression threshold that distinguishes positive from negative SLFN11 patients. Patients with sub-clonal SLFN11 indicated by a red dot. e, f Kaplan–Meier survival curves of (e) progression-free interval (PFI) and (f) overall survival (OS) of high (>30 H-score SLFN11) vs. low SLFN11 ( ≤ 30 H-score SLFN11) subgroups in the 34 patients with high-grade serous ovarian cancer treated with carboplatin and paclitaxel doublet. Events table with patients at risk shown for each timepoint.